Preview
Description
Asthma is a complex and heterogeneous chronic disease that manifests differently across patient populations, influenced by factors such as age, ethnicity, and comorbid conditions. This program explores the underlying role of type 2 inflammation in asthma pathophysiology and highlights how biomarkers—including eosinophil counts, fractional exhaled nitric oxide (FeNO), and IgE levels—can inform a more personalized approach to treatment. Participants will examine emerging evidence supporting the use of biomarker testing to define asthma phenotypes and optimize therapeutic strategies. Building on the latest Global Initiative for Asthma (GINA 2025) recommendations, this provides guidance on assessing disease severity, evaluating comorbidities, and identifying patients most likely to benefit from biologic therapy. Clinical data and practical decision-making frameworks will be reviewed that compare anti-IgE, anti–IL-5/5R, anti–IL-4/13, and anti–TSLP biologics, emphasizing their safety, efficacy, and demonstrated benefits in reducing exacerbations and improving lung function.
What's New
Version 1.1.5 2026-10-17
Updated content. Technical Analysis
Package Overview Basic metadata
Bundle ID
com.mlg.mtosasthma Current Version 1.1.5
Minimum iOS 13.0
Package Size App Store Size
Package Metadata 0 / 2 version records
Detailed binary, privacy manifest, framework, and Info.plist results have not been indexed for this package yet. The verified App Store and archive metadata above remains available.
Developer Information
Known Version Records
0 version records with stored package metadata • 2 known version records
Stored metadata does not guarantee a package is currently available to download.
| Details | Version / IDs | Version date | Action |
|---|---|---|---|
| Not archived | App Store ID: 885691343 | Unknown | Request Version |
| Not archived | App Store ID: 878968754 | Unknown | Request Version |